Beltran, Himisha

Publications

Sort by

Co-Author Network

selected publications

Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer. Molecular cancer therapeutics. 2025 Academic Article GET IT
Prognostic Significance of RB1 Alterations on Outcomes in Metastatic Prostate Cancer. JCO precision oncology. 2025 Academic Article GET IT
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader molecules. 2025 GET IT
EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer. 2025 GET IT
Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression. Cancer research. 2025 Academic Article GET IT
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. Frontiers in oncology. 2025 Review GET IT
State of the art - biomarkers in advanced prostate cancer. Nature reviews. Urology. 2025 Academic Article GET IT
EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer. 2025 GET IT
Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations. JCO precision oncology. 2025 Academic Article GET IT
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer. European urology. 2025 Academic Article GET IT
Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations. The Journal of molecular diagnostics : JMD. 2025 Academic Article GET IT
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care. European urology. 2025 Review GET IT
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer. European urology oncology. 2025 Academic Article GET IT
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer. European urology oncology. 2025 Academic Article GET IT
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer. Nature communications. 2025 Academic Article GET IT
MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy. JCI insight. 2025 Academic Article GET IT
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress. Nature communications. 2025 Academic Article GET IT
Glypican-3 as a Radiotheranostic Target for Neuroendocrine Prostate Cancer. European urology. 2025 Letter GET IT
A pilot study of [¹⁸F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy. European journal of nuclear medicine and molecular imaging. 2025 Academic Article GET IT
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation. Cancer cell. 2025 Academic Article GET IT
Times cited: 4
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance). European urology open science. 2025 Academic Article GET IT
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Guideline GET IT
Times cited: 3
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. 2025 GET IT
Targeting the tumour cell surface in advanced prostate cancer. Nature reviews. Urology. 2025 Review GET IT
Times cited: 1
Racial variation in the advanced prostate cancer genome. Prostate cancer and prostatic diseases. 2025 Academic Article GET IT
A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer. NPJ precision oncology. 2025 Academic Article GET IT
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025 Review GET IT
Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2025 Academic Article GET IT
Times cited: 1
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes. Cancer discovery. 2025 Academic Article GET IT
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer research communications. 2025 Academic Article GET IT
Times cited: 2
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma. BMJ oncology. 2025 Academic Article GET IT
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Guideline GET IT
Times cited: 10
In Memory of Dr. Felix Feng. European urology. 2025 Academic Article GET IT
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO oncology practice. 2024 Academic Article GET IT
Clinical Implementation of Minimal Residual Disease Testing in Genitourinary Cancers: Bridging Promise and Practice. European urology. 2024 Editorial Article GET IT
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients. Nature communications. 2024 Academic Article GET IT
Times cited: 4
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2024 Academic Article GET IT
Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nature communications. 2024 Academic Article GET IT
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. European urology oncology. 2024 Academic Article GET IT
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201). Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Academic Article GET IT
Times cited: 5
Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer. European urology. 2024 Editorial Article GET IT
Characterization of Wnt Signaling Pathway Aberrations in Metastatic Prostate Cancer. Molecular cancer research : MCR. 2024 Academic Article GET IT
Times cited: 1
A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer. 2024 GET IT
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Epigenomics. 2024 Conference Paper GET IT
MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. Cancer research communications. 2024 Academic Article GET IT
Times cited: 6
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nature communications. 2024 Academic Article GET IT
Times cited: 16
The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate. Clinical genitourinary cancer. 2024 Academic Article GET IT
Times cited: 1
Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. The Journal of clinical investigation. 2024 Academic Article GET IT
Times cited: 14
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nature reviews. Urology. 2024 Review GET IT
Times cited: 41
Insulin resistance during androgen deprivation therapy in men with prostate cancer. Cancer. 2024 Academic Article GET IT
Times cited: 2
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU open plus. 2024 Academic Article GET IT
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU open plus. 2024 Academic Article GET IT
Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small. The oncologist. 2024 Academic Article GET IT
Times cited: 3
Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. 2024 GET IT
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. Prostate cancer and prostatic diseases. 2024 Academic Article GET IT
Times cited: 2
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. 2024 GET IT
Non-invasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer discovery. 2024 Academic Article GET IT
G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer. PNAS nexus. 2024 Academic Article GET IT
Times cited: 5
Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes. European urology. 2023 Review GET IT
Times cited: 22
Metabolically regulated lineages in prostate cancer. Nature cell biology. 2023 Academic Article GET IT
Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Science translational medicine. 2023 Academic Article GET IT
Times cited: 27
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases. 2023 GET IT
Evolution of structural rearrangements in prostate cancer intracranial metastases. NPJ precision oncology. 2023 Academic Article GET IT
Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial. Journal of the National Cancer Institute. 2023 Academic Article GET IT
The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity. Cancer discovery. 2023 Review GET IT
Times cited: 60
The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer research communications. 2023 Academic Article GET IT
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. The Journal of clinical investigation. 2023 Academic Article GET IT
Times cited: 14
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Annals of oncology : official journal of the European Society for Medical Oncology. 2023 Academic Article GET IT
Times cited: 37
Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers. Molecular cancer research : MCR. 2023 Academic Article GET IT
Times cited: 12
The Immunogenomic Landscape of Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nature cancer. 2023 Academic Article GET IT
Times cited: 73
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 20
Impact of early detection on cancer curability: A modified Delphi panel study. PloS one. 2022 Academic Article GET IT
Times cited: 8
The NOGO receptor NgR2, a novel αVβ3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Scientific reports. 2022 Academic Article GET IT
Times cited: 6
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. The oncologist. 2022 Review GET IT
Times cited: 52
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. The Journal of clinical investigation. 2022 Academic Article GET IT
Times cited: 18
Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. JCO precision oncology. 2022 Academic Article GET IT
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer research. 2022 Academic Article GET IT
Times cited: 6
Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. European urology focus. 2022 Academic Article GET IT
Times cited: 1
Future directions for precision oncology in prostate cancer. The Prostate. 2022 Review GET IT
Times cited: 32
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 8
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science (New York, N.Y.). 2022 Academic Article GET IT
Editorial: Metastatic prostate cancer: a wealth of data to put into practice. Current opinion in urology. 2022 Editorial Article GET IT
Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clinical advances in hematology & oncology : H&O. 2022 Academic Article GET IT
Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clinical advances in hematology & oncology : H&O. 2022 Academic Article GET IT
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 48
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. The Journal of pathology. 2022 Academic Article GET IT
Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2022 Academic Article GET IT
Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Review GET IT
Times cited: 1
Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian journal of andrology. 2022 Letter GET IT
Times cited: 4
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. The Journal of biological chemistry. 2021 Academic Article GET IT
Times cited: 12
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 83
Towards Biologically Driven Decision-making in Metastatic Hormone-sensitive Prostate Cancer. European urology oncology. 2021 Editorial Article GET IT
Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology. European urology. 2021 Editorial Article GET IT
Times cited: 1
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature communications. 2021 Academic Article GET IT
Extracellular Matrix in Synthetic Hydrogel-based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 inhibitors. Advanced materials (Deerfield Beach, Fla.). 2021 Academic Article GET IT
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. International journal of cancer. 2021 Academic Article GET IT
Times cited: 9
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 98
Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. 2021 GET IT
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature cell biology. 2021 Academic Article GET IT
Times cited: 108
Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer genetics. 2021 Academic Article GET IT
Times cited: 1
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 25
Prostate cancer. Lancet (London, England). 2021 Review GET IT
Times cited: 412
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ precision oncology. 2021 Academic Article GET IT
Therapy considerations in neuroendocrine prostate cancer: what next?. Endocrine-related cancer. 2021 Review GET IT
Times cited: 66
Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. European urology open science. 2021 Academic Article GET IT
Times cited: 4
Epigenetics in prostate cancer: clinical implications. Translational andrology and urology. 2021 Review GET IT
Times cited: 48
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications biology. 2021 Academic Article GET IT
Times cited: 7
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 55
The treatment landscape of metastatic prostate cancer. Cancer letters. 2021 Review GET IT
Times cited: 95
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nature communications. 2021 Academic Article GET IT
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology. 2021 Academic Article GET IT
Times cited: 28
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 105
Transcriptional mediators of treatment resistance in lethal prostate cancer. Nature medicine. 2021 Academic Article GET IT
Times cited: 119
Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer research. 2021 Academic Article GET IT
Times cited: 47
Clinical considerations for the management of androgen indifferent prostate cancer. Prostate cancer and prostatic diseases. 2021 Review GET IT
Times cited: 42
Clinical and Biological Features of Neuroendocrine Prostate Cancer. Current oncology reports. 2021 Review GET IT
Times cited: 181
Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2020 Conference Paper GET IT
Times cited: 11
Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 29
Accelerating precision medicine in metastatic prostate cancer. Nature cancer. 2020 Academic Article GET IT
Times cited: 60
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature communications. 2020 Academic Article GET IT
Times cited: 102
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. European urology. 2020 Academic Article GET IT
Times cited: 36
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA network open. 2020 Academic Article GET IT
Times cited: 93
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 88
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Conference Paper GET IT
Times cited: 216
Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells. Journal of extracellular vesicles. 2020 Academic Article GET IT
Times cited: 36
ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. Bioinformatics (Oxford, England). 2020 Academic Article GET IT
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 142
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Molecular oncology. 2020 Academic Article GET IT
Times cited: 23
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. Molecular cancer therapeutics. 2020 Academic Article GET IT
Docetaxel for Early Prostate Cancer: What Have We Learned?. European urology. 2020 Editorial Article GET IT
Times cited: 4
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO oncology practice. 2020 Academic Article GET IT
Times cited: 8
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European urology. 2020 Conference Paper GET IT
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 59
Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 Academic Article GET IT
Times cited: 12
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 166
Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 71
Towards precision oncology in advanced prostate cancer. Nature reviews. Urology. 2019 Review GET IT
Times cited: 187
The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. European urology. 2019 Editorial Article GET IT
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 36
Clinical features of neuroendocrine prostate cancer. European journal of cancer. 2019 Academic Article GET IT
Times cited: 251
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 64
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 12
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 28
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 175
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 131
Erratum: CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. 2019 GET IT
Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European urology oncology. 2019 Academic Article GET IT
Times cited: 18
Retinoblastoma Loss in Cancer: Casting a Wider Net. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Comment GET IT
Times cited: 5
Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 966
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. EBioMedicine. 2019 Academic Article GET IT
Times cited: 42
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 Academic Article GET IT
Times cited: 33
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer cell. 2019 Academic Article GET IT
Times cited: 79
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Science translational medicine. 2019 Academic Article GET IT
Times cited: 156
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer cell. 2019 Academic Article GET IT
Times cited: 157
Biological Evolution of Castration-resistant Prostate Cancer. European urology focus. 2019 Review GET IT
Times cited: 92
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. Cold Spring Harbor perspectives in medicine. 2019 Review GET IT
Times cited: 92
The application of precision medicine in diagnosing familial Mediterranean fever. Leukemia & lymphoma. 2019 Letter GET IT
ONECUT2 is a driver of neuroendocrine prostate cancer. Nature communications. 2019 Academic Article GET IT
Times cited: 188
Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2018 Academic Article GET IT
Times cited: 8
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. 2018 GET IT
Times cited: 34
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Scientific reports. 2018 Academic Article GET IT
Times cited: 23
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 211
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nature communications. 2018 Academic Article GET IT
Times cited: 106
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. The Journal of pathology. 2018 Academic Article GET IT
Times cited: 18
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 23
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 590
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018 Academic Article GET IT
Times cited: 537
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy. JCO precision oncology. 2018 Academic Article GET IT
Patient derived organoids to model rare prostate cancer phenotypes. Nature communications. 2018 Academic Article GET IT
Times cited: 288
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience. 2018 Academic Article GET IT
Times cited: 60
CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2018 Academic Article GET IT
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 70
The long tail of oncogenic drivers in prostate cancer. Nature genetics. 2018 Academic Article GET IT
Times cited: 637
Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nature reviews. Urology. 2018 Review GET IT
Times cited: 308
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. European urology. 2018 Academic Article GET IT
Times cited: 112
Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer. 2017 Academic Article GET IT
Times cited: 50
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer cell. 2017 Academic Article GET IT
Times cited: 62
Rapid autopsy of a patient with recurrent anaplastic ependymoma. 2017 GET IT
Times cited: 5
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European urology. 2017 Conference Paper GET IT
Times cited: 307
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 45
Biology and evolution of poorly differentiated neuroendocrine tumors. Nature medicine. 2017 Academic Article GET IT
Times cited: 172
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harbor molecular case studies. 2017 Academic Article GET IT
Times cited: 23
Emerging Variants of Castration-Resistant Prostate Cancer. Current oncology reports. 2017 Review GET IT
Times cited: 155
Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. Nature biotechnology. 2017 Academic Article GET IT
Times cited: 202
On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study. Anticancer research. 2017 Academic Article GET IT
Times cited: 10
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer discovery. 2017 Academic Article GET IT
Times cited: 800
The clone wars. Science translational medicine. 2017 Comment GET IT
Times cited: 1
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.). 2017 Academic Article GET IT
Times cited: 823
Prostate cancer in 2016: Improved outcomes and precision medicine come within reach. Nature reviews. Urology. 2017 Information Resource GET IT
Times cited: 2
Unleashing the wrath of Ras. Science translational medicine. 2017 Comment GET IT
Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2017 Review GET IT
Times cited: 14
Synthetic lethality and beyond. Science translational medicine. 2016 Comment GET IT
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer discovery. 2016 Academic Article GET IT
Times cited: 305
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 241
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer cell. 2016 Academic Article GET IT
Times cited: 437
Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. NPJ genomic medicine. 2016 Academic Article GET IT
Times cited: 71
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1370
Update on the biology and management of neuroendocrine prostate cancer. Clinical advances in hematology & oncology : H&O. 2016 Article GET IT
Times cited: 11
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European urology. 2016 Academic Article GET IT
Times cited: 143
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
PO-43 - Differential coagulation factor expression in neuroendocrine prostate cancer (PC), metastatic castrate-resistant PC, and localized prostatic adenocarcinoma. Thrombosis research. 2016 Academic Article GET IT
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature medicine. 2016 Academic Article GET IT
Times cited: 1285
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016 Academic Article GET IT
Times cited: 18
The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 119
An emerging role for cytopathology in precision oncology. Cancer cytopathology. 2015 Academic Article GET IT
Times cited: 22
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell reports. 2015 Academic Article GET IT
Times cited: 217
Prostate cancer: Intrapatient heterogeneity in prostate cancer. Nature reviews. Urology. 2015 Comment GET IT
Times cited: 19
Integrative Clinical Genomics of Advanced Prostate Cancer. 2015 GET IT
Times cited: 228
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 240
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2712
CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget. 2015 Academic Article GET IT
Times cited: 24
Prioritizing precision medicine for prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Editorial Article GET IT
Times cited: 8
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 60
ERG induces taxane resistance in castration-resistant prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 107
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 555
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Academic Article GET IT
Times cited: 1255
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome biology. 2014 Academic Article GET IT
Times cited: 82
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Human pathology. 2014 Academic Article GET IT
Times cited: 32
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 457
Aggressive variants of castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Review GET IT
Times cited: 349
The many faces of neuroendocrine differentiation in prostate cancer progression. Frontiers in oncology. 2014 Review GET IT
Times cited: 203
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential. Molecular cancer research : MCR. 2014 Review GET IT
Times cited: 123
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer research. 2013 Academic Article GET IT
Times cited: 301
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature biotechnology. 2013 Academic Article GET IT
Times cited: 1813
Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 49
Punctuated evolution of prostate cancer genomes. Cell. 2013 Academic Article GET IT
Times cited: 1070
Epigenomic alterations in localized and advanced prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
DNA mismatch repair in prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 12
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (New York, N.Y.). 2013 Academic Article GET IT
Times cited: 218
New strategies in prostate cancer: translating genomics into the clinic. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Review GET IT
Times cited: 50
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer research. 2012 Academic Article GET IT
Times cited: 157
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. European urology. 2012 Academic Article GET IT
Times cited: 382
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. The Journal of pathology. 2012 Academic Article GET IT
Times cited: 159
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 43
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. 2012 GET IT
Times cited: 31
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer discovery. 2011 Academic Article GET IT
Times cited: 795
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU international. 2011 Information Resource GET IT
Times cited: 20
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian journal of andrology. 2011 Article GET IT
Times cited: 2
New therapies for castration-resistant prostate cancer: efficacy and safety. European urology. 2011 Information Resource GET IT
Times cited: 114

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation awarded by Prostate Cancer Foundation Co-Investigator 2017 - 2025

more ...

less ...

Background

education and training

M.D., New York Medical College 2004
B.S., University of Oregon 2000

Contact

full name

Himisha Beltran

primary email

hip9004@med.cornell.edu

VIVO Weill Cornell Medical College

Himisha Beltran Adjunct Associate Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email